A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma

Trial Profile

A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.
    • 03 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 15 Aug 2014 Planned End Date changed from 1 Jun 2016 to 1 Oct 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top